GSK, Wavre, Belgium.
Keyrus Biopharma c/o GSK, Wavre, Belgium.
Health Policy. 2017 Dec;121(12):1303-1312. doi: 10.1016/j.healthpol.2017.08.010. Epub 2017 Sep 21.
Many countries struggle with the prioritisation of introducing new vaccines because of budget limitations and lack of focus on public health goals. A model has been developed that defines how specific health goals can be optimised through immunisation within vaccination budget constraints.
Japan, as a country example, could introduce 4 new pediatric vaccines targeting influenza, rotavirus, pneumococcal disease and mumps with known burden of disease, vaccine efficacies and maximum achievable coverages. Operating under budget constraints, the Portfolio-model for the Management of Vaccines (PMV) identifies the optimal vaccine ranking and combination for achieving the maximum QALY gain over a period of 10 calendar years in children <5 years old. This vaccine strategy, of interest and helpful for a healthcare decision maker, is compared with an unranked vaccine selection process.
Results indicate that the maximum QALY gain with a fixed annual vaccination budget of 500 billion Japanese Yen over a 10-year period is 72,288 QALYs using the optimal sequence of vaccine introduction (mumps [1st], followed by influenza [2nd], rotavirus [3rd], and pneumococcal [4th]). With exactly the same budget but without vaccine ranking, the total QALY gain can be 20% lower.
The PMV model could be a helpful tool for decision makers in those environments with limited budget where vaccines have to be selected for trying to optimise specific health goals.
许多国家由于预算限制和缺乏对公共卫生目标的关注,在优先引入新疫苗方面存在困难。已经开发出一种模型,该模型定义了如何通过免疫接种预算限制内的疫苗接种来优化特定的健康目标。
以日本为例,可以针对流感、轮状病毒、肺炎球菌病和腮腺炎引入 4 种新的儿科疫苗,这些疫苗具有已知的疾病负担、疫苗效力和最大可实现覆盖率。在预算限制下,疫苗管理投资组合模型(PMV)确定了最佳疫苗排名和组合,以在 10 个日历年内使 5 岁以下儿童的 QALY 增益最大化。这种疫苗策略对于医疗保健决策者来说是有意义和有帮助的,与无排名的疫苗选择过程进行了比较。
结果表明,在 10 年内每年固定接种预算为 5000 亿日元的情况下,使用最佳疫苗接种顺序(腮腺炎[第 1 位],其次是流感[第 2 位]、轮状病毒[第 3 位]和肺炎球菌[第 4 位])可获得最大 QALY 增益 72288 个。如果没有疫苗排名,并且使用完全相同的预算,则总 QALY 增益可能会低 20%。
PMV 模型可以成为那些预算有限、必须选择疫苗以优化特定健康目标的环境中决策者的有用工具。